When did REIG JOFRE announce the Leanbio transaction?

REIG JOFRE announced the transaction on 2 December 2025. The announcement covers the increase in its Leanbio shareholding and the broader integration of Leanbio’s biotechnology capabilities into REIG JOFRE’s business model.

How much did REIG JOFRE pay to increase its stake in Leanbio?

REIG JOFRE paid a total consideration of 3.5 million euros to acquire equity interests from Leanbio’s existing shareholders. This increased REIG JOFRE’s stake from 47% to 85%.

What percentage of Leanbio does REIG JOFRE now own?

REIG JOFRE’s shareholding in Leanbio has increased to 85%, from the previous 47%. The remaining 15% of Leanbio’s share capital remains with the founding team and specialised investors.

What does Leanbio do and what capabilities does it bring to REIG JOFRE?

Leanbio is a Barcelona-based biotechnology company focused on the design, development, characterisation and production of biotechnology-based active pharmaceutical ingredients. It contributes capabilities in recombinant proteins, antibodies, plasmid DNA and RNA technologies.

How does the Leanbio integration change REIG JOFRE’s biotechnology business?

The integration expands REIG JOFRE’s activity across the research, design, process development, industrial production and scale-up phases of biological medicines. The announcement says this gives REIG JOFRE an end-to-end offering from active ingredient development through to final injectable products under GMP standards.

What is REIG JOFRE’s existing relationship with Leanbio?

The relationship began in 2018 with the creation of Syna Therapeutics, a 50/50 joint venture between REIG JOFRE and Leanbio for developing biosimilars. REIG JOFRE later entered Leanbio’s share capital with an additional 10%, and the relationship was further strengthened in 2024 through an investment of 6.6 million euros in a new biotech drug substance plant.

Where is Leanbio’s new biotech manufacturing plant located and what will it produce?

The new GMP-certified biotech drug substance plant is being built in Barcelona, at Sant Quirze del Vallès. The facility is around 4,000 m² and is equipped to produce recombinant proteins, antibodies, plasmid DNA and mRNA, alongside development laboratories, scale-up areas, pilot plants and quality control facilities.

When is REIG JOFRE’s new Leanbio-related plant expected to start operations?

The plant is expected to start operations in mid-2026. The announcement says it is expected to employ more than one hundred professionals once it reaches full capacity.

What does REIG JOFRE say the Leanbio integration will do for customers?

REIG JOFRE says combining the companies’ capabilities will accelerate the time-to-market of new therapies and biosimilars. It also says the combined business will support customers throughout the process, from the laboratory to the finished product.

What does REIG JOFRE’s CEO say about the outlook for the biotechnology business?

REIG JOFRE’s CEO describes the transaction as a strategic milestone and says the integration creates a platform combining Leanbio’s expertise in biotechnological active pharmaceutical ingredients with REIG JOFRE’s industrial capabilities in sterile injectables. The CEO also says REIG JOFRE expects the sector to continue growing over the next decade.

Where do REIG JOFRE’s shares trade and what is its ticker symbol?

REIG JOFRE is listed on the Spanish stock market’s continuous market, with the ticker symbol BME:RJF.

What does REIG JOFRE do?

REIG JOFRE is a biopharmaceutical company that develops, manufactures, markets and distributes essential healthcare solutions. Following the Leanbio integration, the announcement describes the company as capable of covering the full life cycle of biological medicines, from active ingredient development to final injectable products under GMP standards.

Home
News Intelligence
Laboratorio Reig Jofre S.A.
REIG JOFRE announces increase in Leanbio stake to 85% for 3.5 million euros

Back to all Laboratorio Reig Jofre S.A. press releases

Laboratorio Reig Jofre S.A.

BME:RJF

REIG JOFRE announces increase in Leanbio stake to 85% for 3.5 million euros

Published Tuesday, 02 December 2025

Get alerts

Plain English summaries when Laboratorio Reig Jofre S.A. announces news.

At a glance

Company: Laboratorio Reig Jofre S.A.
Listings: BME:RJF
Announcement type: Merger or acquisition
Published: Tuesday, 02 December 2025
Source announcement: reigjofre.com

Key figures
Measure	Figure	Period
REIG JOFRE’s shareholding in LEANBIO, S.L.	85%	Not stated
Total consideration	3.5 million euros	Not stated
Investment	6.6 million euros	2024

Figures are quoted from this announcement and selected automatically.

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

REIG JOFRE (BME:RJF) announces it has consolidated its stake in Leanbio and says the transaction expands its biological-medicine capabilities.

REIG JOFRE says its Leanbio stake moved from 47% to 85% through purchases from existing shareholders for 3.5 million euros.
The remaining 15% of Leanbio is held by the founding team and specialized investors.
Leanbio contributes capabilities for developing, characterizing and producing recombinant proteins, antibodies, plasmid DNA and RNA technologies.
A 2024 investment of 6.6 million euros funded a GMP-certified plant in Barcelona’s Sant Quirze del Vallès, around 4,000 m².
The company expects the plant to start operations in mid-2026 and employ more than one hundred professionals at full capacity.

The company says the integration covers research, design, process development, industrial production and scale-up phases for biological medicines.

Investor FAQs

REIG JOFRE announced that it had increased its stake in Leanbio, S.L. from 47% to 85% by acquiring equity interests from existing shareholders for a total consideration of 3.5 million euros. The remaining 15% is held by Leanbio’s founding team and specialised investors.

Source announcement

Company: Laboratorio Reig Jofre S.A.
Title: REIG JOFRE acquires Leanbio and strengthens its vertical integration in biotechnology
Published: Tuesday, 02 December 2025
Source site: reigjofre.com

Read the source announcement on reigjofre.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…